Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
Active, not recruitingPhase 2NCT02754752
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This randomized phase II trial studies how well electroacupuncture therapy works in reducing chronic pain in patients following surgery for stage I-III breast cancer. Electroacupuncture therapy is a type of complementary integrative medicine in which pulses of weak electrical current are sent through very thin, solid, sterile, stainless steel needles into certain points in the skin. Electroacupuncture therapy may help to lower pain and other surgery-related symptoms.
Study details
- Official title
- Randomized-Controlled Trial of Acupuncture for Chronic Pain After Breast Cancer Treatment
- Conditions
- Stage I Breast Cancer AJCC v7
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Interventions
- Procedure: Electroacupuncture Therapy
- Procedure: Electroacupuncture Therapy
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Sponsor
- M.D. Anderson Cancer Center
- Collaborators
- Gateway for Cancer Research; National Cancer Institute (NCI)
- Start date
- 2016-09-13
- Primary completion
- 2026-12-31
- Sex
- Female
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Be adult women \>/= 18 years of age. * Be able to read, write, and speak English * Able to give informed consent * Have a history of stage I, II, or III breast cancer * Have a documented visit with an oncologist during the previous 12-months * Have no current evidence of disease * Have persistent pain (unrelated to aromatase inhibitors or chemotherapy-induced peripheral neuropathy) for at least 3 months following treatment for breast cancer * Have pain severity (arithmetic mean of four pain severity items) \>= 2 on Brief Pain Inventory (BPI) * Have worst pain \>= to 4 (0-10 numeric rating scale \[NRS\]) in the preceding week * Be willing and able to adhere to all study-related procedures * Have completed all cancer treatment (including surgery, chemotherapy and/or radiation) at least 4 months prior to enrollment * Have documented lab work with absolute neutrophil count (ANC) \>= 1.0 K/uL and platelets \>= 50 K/uL in the past 12 months * If applicable, maintain self-management of lymphedema symptoms being performed at home at time of study entry Exclusion Criteria: * Metastatic breast cancer (stage IV) * Known bleeding disorder per patient reported history * Cardiac pacemaker or other implanted electronic devices * New or planned new lymphedema treatment during the study period * Currently receiving or ever received acupuncture for present pain condition * Received acupuncture with electrical stimulation for any condition * Received acupuncture for any condition in the past year
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02754752